Relmada Therapeutics, Inc. - Common Stock (RLMD)

Let's have a look at the stocks with an unusual volume in today's session.

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

These stocks have an unusual volume in today's session

Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.

RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.

RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million.

The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.